Showing results (1-10 of 43) with videos related to

Sort By:
Pageof 5
Hematology. American Society of Hematology. Education Program|February 20, 2015
A practical approach to relapsed multiple myelomaJoseph R Mikhael
Leukemia Research Reports|December 28, 2013
New diagnosis of multiple myeloma in a patient with mantle cell lymphoma: Shared genetic factors or simple coincidence?Mutende J Sikuyayenga, Craig B Reeder, Joseph R Mikhael
Teaching and Learning in Medicine|October 12, 2013
The effects of deliberate practice and feedback to teach standardized handoff communication on the knowledge, attitudes, and practices of first-year residentsAdam P Sawatsky, Joseph R Mikhael, Ankit D Punatar, et al.
Current Oncology (Toronto, Ont.)|February 24, 2023
Multisite Quality Improvement Initiative to Identify and Address Racial Disparities and Deficiencies in Delivering Equitable, Patient-Centered Care for Multiple Myeloma-Exploring the Differences between Academic and Community Oncology CentersJoseph R Mikhael, Shelby L Sullivan, Jeffrey D Carter, et al.
Leukemia & Lymphoma|September 17, 2015
Current imaging follow-up of non-Hodgkin lymphoma exposes patients to significant radiation but does not detect asymptomatic relapsesEloisa Riva, Carolina Oliver, Maria del Carmen Pérez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2026
Past, Present, and Future of Dexamethasone in Multiple Myeloma and AL AmyloidosisRahul Banerjee, Tracy King, Beth Faiman, et al.
Leukemia & Lymphoma|September 24, 2016
Second-line therapy in diffuse large B-cell lymphoma (DLBCL): treatment patterns and outcomes in older patients receiving outpatient chemotherapyMark D Danese, Robert I Griffiths, Michelle L Gleeson, et al.
Chest|August 5, 2011
Acute lung toxicity related to pomalidomideHolly L Geyer, Robert W Viggiano, Martha Q Lacy, et al.
Leukemia & Lymphoma|February 1, 2017
Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myelomaDan T Vogl, Thomas G Martin, Ravi Vij, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 26, 2014
Activity of 129 single-agent drugs in 228 phase I and II clinical trials in multiple myelomaK Martin Kortuem, Kaitlyn Zidich, Steven R Schuster, et al.
Pageof 5